Attorneys will scour for online ‘dirt’ to use in a lawsuit, writes Brianne Goodwin, JD, RN.
Modifier use without supporting documentation could be considered fraudulent, write Ray Painter, MD, and Mark Painter.
Data from a recent study also indicate that overactive bladder patients discontinue pharmacotherapy long-term despite chronic symptoms.
Until now there has been no large, thorough investigation into the risk of clean intermittent catheterization in patients undergoing repeat injections of onabotulinumtoxinA.
"Concerns about scope of practice aside, there is no doubt that as the demand for urologic services increases and the number of practicing urologists decreases, we will need to find alternative ways to continue to see and treat our patients," writes Henry Rosevear, MD.
A nickel-sized leadless titanium device, implanted in patients’ ankles, could provide years of relief from overactive bladder syndrome.
The oral beta-3 agonist vibegron, taken once daily at either 50 mg or 100 mg, is well tolerated and results in clinically and statistically significant reductions in daily micturitions, urge incontinence, and urgency episodes.
In this article, we review the underlying causes of nocturia and outline an approach to its diagnostic evaluation and treatment.
Researchers have reported an association with the release of the AUA/SUFU Adult Urodynamics Guideline and reduction of urodynamics performed for diagnosis of overactive bladder, stress urinary incontinence, and mixed urinary incontinence.
General urologists are less likely to utilize third-line interventions for overactive bladder than those with additional female pelvic medicine and reconstructive surgery training.